JDD Highlights
The June issue of the Journal of Drugs in Dermatology is available now. This month, we focus on Acne and Rosacea, with special features on Public Health, Anti-aging, Aesthetic, and Medical Dermatology.
Read the JDD Now
Acne, Rosacea, Public Health, Anti-Aging, Aesthetic, and Medical Dermatology
The June issue of the Journal of Drugs in Dermatology is available now. This month, we focus on Acne and Rosacea, with special features on Public Health, Anti-aging, Aesthetic, and Medical Dermatology.
Article Highlights
- Guest Editor Dr. James Q. Del Rosso stresses that even the best case scenario of teledermatology can never offer the same as a live in-person visit in Virtual Exams No Substitute for In-Person Care of Acne and Rosacea.
- Treating Inflammation in Rosacea: Current Options and Unmet Needs, authors discuss the underlying inflammatory nature of rosacea, treatments that target these inflammatory processes, and shortcomings of current therapies.
- An expert panel of pediatric dermatologists and dermatologists provide information on differential diagnosis, prevention, treatment, and maintenance in Consensus on Neonatal Through Preadolescent Acne.
- Tazarotene 0.045% lotion was efficacious and well tolerated in New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
-
Authors discuss a promising therapeutic option for improving scar appearance following surgery for NMSCs in Improving the Appearance of Surgical Facial Scars With IncobotulinumtoxinA and Microneedling.
Editor's Picks
You May Also Like
Bensal HP Treatment for Burn and Excision Wounds: An In-Vivo Assessment of Wound Healing Efficacy and Immunological Impact
Bensal HP Treatment for Burn and Excision Wounds: An In-Vivo Assessment of Wound Healing Efficacy and Immunological Impact
Wound Care Is Trending: A JDD Vault Pick on Bensal HP and Repair This is a must-read article from JDD. Wound care is a hot topic in dermatology and that is…
Dermatology Roundup: New Regimen and Label Expansion in Inflammatory Skin Disease Treatments
Dermatology Roundup: New Regimen and Label Expansion in Inflammatory Skin Disease Treatments
The U.S. Food & Drug Administration (FDA) recently adopted changes to the approvals of two medications for inflammatory skin diseases. Ebglyss (lebrikizumab-lbkz) has a newly approved regimen of one maintenance…
From Endpoint to Exam Room: Understanding What Psoriasis Trials Really Tell Us
From Endpoint to Exam Room: Understanding What Psoriasis Trials Really Tell Us
Not all psoriasis data tell the same story, and sometimes the loudest signal isn't the most important one. In this episode of the JDD Podcast, host Dr. Adam Friedman sits…
